- Astermark J, Rocino A, von Depka M, Van Den Berg HM, Gringeri A, Mantovani LG, Morado M,Garrido RP, Schiavoni M, Villar A, Windyga J; EHTSB.
Current use of by-passing agents in Europe in the management of acute bleeds in patients with
haemophilia and inhibitors.
Haemophilia. 2007;13(1):38-45. - Lang T, von Depka M.
Diagnostische Möglichkeiten und Grenzen der Thrombelastometrie/-graphie
Hämostaseologie. 2006;26(3 Suppl 1):S20-9. - Lang T, von Depka M.
Diagnostische Möglichkeiten und Grenzen der Thrombelastometrie/-graphie
Hämostaseologie. 2006;26(3 Suppl 1):S20-9. - Astermark J, Morado M, Rocino A, van den Berg HM, von Depka M, Gringeri A,
Mantovani L, Garrido RP, Schiavoni M, Villar A, Windyga J; EHTSB.
Current European practice in immune tolerance induction therapy in patients with haemophilia
and inhibitors.
Haemophilia. 2006;12(4):363-71. - Von Depka M, Hassan M, Blatny J, Smejkal P, Vdovin V.
The use of recombinant-activated factor VII in von Willebrand disease: a case series.
Blood Coagul Fibrinolysis. 2006;17(4):311-6. - Templin C, Schaefer A, Stumme B, Drexler H, von Depka M.
Combined aspirin and clopidogrel resistance associated with recurrent coronary stent thrombosis.
Clin Res Cardiol. 2006;95(2):122-6. - Tacke F, Fiedler K, von Depka M, Luedde T, Hecker H, Manns MP, Ganser A, Trautwein C.
Clinical and prognostic role of plasma coagulation factor XIII activity for bleeding disorders and
6-year survival in patients with chronic liver disease.
Liver Int. 2006;26(2):173-81. - Ludlam CA, Powderly WG, Bozzette S, Diamond M, Koerper MA, Kulkarni R, Ritchie B, Siegel J,
Simmonds P, Stanley S, Tapper ML, von Depka M.
Clinical perspectives of emerging pathogens in bleeding disorders.
Lancet. 2006 Jan 21;367(9506):252-61. - Von Depka M.
Managing acute bleeds in the patient with haemophilia and inhibitors: options, efficacy and safety.
Haemophilia. 2005;11 Suppl 1:18-23. - von Auer Ch, Oldenburg J, von Depka M, Escuriola-Ettinghausen C, Kurnik K, Lenk H, Scharrer I.
Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates.
Ann N Y Acad Sci. 2005;1051:498-505. - Pihusch M, Bacigalupo A, Szer J, von Depka Prondzinski M, Gaspar-Blaudschun B, Hyveled L, Brenner B;
Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell
transplantation.
J Thromb Haemost. 2005 Sep;3(9):1935-44. - Von Depka Prondzinski, M.
Hämostasestörungen bei onkologischen Patienten.
Der Internist 2005; 46:48-56 - Schuerholz T, Keil O, Friedrich L, Elsner HA, Marx G, von Depka M, Piepenbrock S, Scheinichen D.
Acute Hyperglycaemia impairs platelet receptor expression in healthy adults in vitro.
Platelet 2005; eingereicht - Mischke R, Wilhelm C, von Depka M.
Hämophilie A und B.
Handlexikon der Tierärztlichen Praxis 2004; 215: 326ga - 326gi - von Depka M.
Immune tolerance therapy in patients with acquired hemophilia.
Hematology. 2004;9(4):245-57. - Poon MC, D'Oiron R, Von Depka M, Khair K, Negrier C, Karafoulidou A, Huth-Kuehne A, Morfini M;
International Data Collection on Recombinant Factor VIIa and Congenital Platelet Disorders Study Group.
Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's
thrombasthenia: results of an international survey.
J Thromb Haemost. 2004;2(7):1096-1103. - Wilhelmi MH, Gratz KF, Mischke R, von Depka M, Noske D, Francis T, Haverich A, Mertsching H.
The ex-vivo-shunt-model: novel approach for assessing the thrombogenicity of vascular implants.
Int J Artif Organs. 2003;26(12):1095-103. - Werwitzke S, Tiede A, Stoll M, von Depka M.
Immune reconstitution inflammatory syndrome (IRIS) as a cause for inhibitor development in hemophilia.
J Thromb Haemost. 2004;2(1):193-4. - R. d?Oiron, M.C. Poon, T. Abshire, C. Berger, P. Beurrier, V. Blanchette, H.A. Britton, A. Chuansumrit, C. Demers, O. Devecioglu, E. Fressinaud, W.B.J. Gerrits, V. Guérin, C. Guethner, M. Heisel, D.S. Houston, A. Huth-Kuehne, A. Karafoulidou, G. Kenet, K. Khair, S. Kuhle, K. Kurnik, S. Lethagen, J. Lorenzo, P.E. Makris, M. Morfini, R. Musso, C. Négrier T. Lambert, L. de Lumley, A. Marquès-Verdier, P. Paugy, B. Pautard, P. Petrini, A. Shapiro, P. Sié, A. Street, L. Tengborn, A. Thomas, M.-F. Torchet, N. Trillot, C. Van Geet, M. von Depka, M. Vicariot, I. Warrier, J. Wilde, M. Winter.
Outcomes from the Glanzmann?s thrombasthenia and recombinant factor VIIa data collection.
Haematologica 2004; 84: 38-40 - Auerswald G, von Depka Prondzinski M, Ehlken B, Kreuz W, Kurnik K, Lenk H, Scharrer I, Schramm W, Zimmermann R.
Treatment Patterns and Cost-of-Illness of Severe Haemophilia in Patients with Inhibitors in Germany.
Haemophilia 2004; 10:499-508 - Tiede A, Eder M, von Depka M, Battmer K, Luther S, Kiem HP, Ganser A, Scherr M.
Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction.
Gene Ther. 2003;10(22):1917-25. - Tacke F, Schoffski P, Trautwein C, Luedde T, Ganser A, Manns MP, von Depka M.
Plasma P-selectin levels are elevated in patients with chronic liver disease.
Blood Coagul Fibrinolysis. 2003 Jun;14(4):319-25. - Von Depka M, Czwalinna A, Wermes C, Eisert R, Scharrer I, Ganser A, Ehrenforth S.
The deletion polymorphism in the angiotensin-converting enzyme gene is a moderate
risk factor for venous thromboembolism.
Thromb Haemost. 2003;89(5):847-52. - Von Depka M.
NovoSeven: mode of action and use in acquired haemophilia.
Intensive Care Med. 2002;28 Suppl 2:S222-7. - Meyer MW, von Depka M, Wilhelm C, Schroder A, Erb C.
Plasminogen activator inhibitor-1 mRNA expression in cultured pigmented ciliary epithelial cells
of the porcine eye.
Graefes Arch Clin Exp Ophthalmol. 2002;240(8):679-86. - Von Depka M, Czwalinna A, Eisert R, Wermes C, Scharrer I, Ganser A, Ehrenforth S.
Prevalence of a 23bp insertion in exon 3 of the endothelial cell protein C receptor gene in venous thrombophilia.
Thromb Haemost. 2001;86(6):1360-2. - Poon MC, d'Oiron R, Hann I, Negrier C, de Lumley L, Thomas A, Karafoulidou A, Demers C, Street A, Huth-Kuhne A, Petrini P,
Fressinaud E, Morfini M, Tengborn L, Marques-Verdier A, Musso R, Devecioglu O, Houston DS, Lethagen S, Van Geet C,
von Depka M, Berger C, Beurrier P, Britton HA, Gerrits W, Guthner C, Kuhle S, Lorenzo JJ, Makris PE, Nohe N, Paugy P,
Pautard B, Torchet MF, Trillot N, Vicariot M, Wilde J, Winter M, Chambost H, Ingerslev J, Peters M, Strauss G.
Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia.
Semin Hematol. 2001;38(4 Suppl 12):21-5. - Tacke F, Schoffski P, Trautwein C, Manns MP, Ganser A, von Depka M.
Tissue factor and thrombomodulin levels are correlated with stage of cirrhosis in patients with liver disease.
Blood Coagul Fibrinolysis. 2001;12(7):539-45. - Benten D, Widjaja A, von Depka M, Flemming P, Trautwein C, Boker K, Vogel A, Rosenau J, Manns MP.
Autoimmune hepatitis associated with coagulation disorders and immunethyreopathy.
Z Gastroenterol. 2001;39(10):837-40. - Von Depka M, Nowak-Gottl U, Eisert R, Dieterich C, Barthels M, Scharrer I, Ganser A, Ehrenforth S.
Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism
Blood. 2000;96(10):3364-8. - Barthels M, Kraus M, Bohn U, Liese B, von Depka M, Eisert R, Ganser A.
Factor VIII inhibitor-tests could be less sensitive than supposed.
Vox Sang. 1999;77 Suppl 1:87-9. - Von Depka M, Czwalinna A, Eisert R, Wermes C, Scharrer I, Ganser A, Ehrenforth S.
Prevalence of a 23bp Insertion in Exon 3 of the Endothelial Cell Protein C Receptor Gene in Venous Thrombophilia.
Thromb Haemostas 2001; 86:1360-1362 - Studt JD, Budde U, Schneppenheim R, Eisert R, von Depka Prondzinski M, Ganser A, Barthels M.
Quantification and Facilitated Comparison of von Willebrand Factor Multimer Patterns by Densitometry.
Am Journal Clinical Pathology 2001; 116:567-574 - Tacke F, Schöffski P, Trautwein C, Manns MP, Ganser A, von Depka Prondzinski M.
Tissue factor and thrombomodulin levels are correlated with stage of cirrhosis in patients with liver disease.
Blood Coag Fibrinol 2001; 12:539-545 - Ehrenforth S, von Depka Prondzinski M.
The Role of Factor XIII Val34Leu Polymorphism in Thrombotic Disease.
J Lab Med 2001; 25:254-261 - Von Depka M, Nowak-Göttl U, Eisert R, Dietrich C, Barthels M, Scharrer I, Ganser A, Ehrenforth S.
Increased lipoprotein (a) as an independent risk factor of venous thromboembolism.
Blood 2000; 96:3364-3368 - Ehrenforth S, Klinke S, von Depka Prondzinski M, Kreuz W, Ganser A, Scharrer I.
APC-Resistenz und venöse Thrombophilie: Molekulargenetische Prävalenzstudie in der deutschen Bevölkerung.
Dtsch med Wschr 1999; 124:783-787 - Ehrenforth S, von Depka Prondzinski M, Aygoren-Pursun E, Nowak-Gottl U, Scharrer I, Ganser A.
Study of the Prothrombin Gene 20201 GA Variant in FV:Q506 Carriers in Relationship to the Presence or Absence of Juvenile Venous Thromboembolism.
Arterioscler Thromb Vasc Biol 1999; 19:276-280 - Berger A, von Depka Prondzinski, Doerr HW, Rabenau H, Weber B.
Hepatitis C plasma viral load is associated with HCV genotype but not with HIV coinfection.
J Med Virol 1996; 48:339-343 - Von Depka Prondzinski M, von Stamm U, Bröcker EB.
Heterogeneity of the T-cell and macrophage infiltrate in cutaneous and subcutanous metastases of melanoma patients.
Melanoma Research 1993; 3: 203-208 - Von Stamm U, Bröcker EB, von Depka Prondzinski M, Ruiter DJ, RümkeP, Broding C, Carrer S, Lejeune FJ.
Effect of systemic interferon-a (IFN-a) on the antigenic phenotype of melanoma metastases. EORTC melanoma group cooperative study No. 18852.
Melanoma Research 1993; 3:173-180 - Von Depka Prondzinski M.
Rituximab for Immune Tolerance in Acquired Hemophilia.
Haematologica, 2004; 89: 8-12 - Benten D, Widjaja A, von Depka Prondzinski M, Flemming P, Trautwein C, Böker K, Vogel R, Rosenau J, Manns MP.
Autoimmune hepatitis associated with coagulation disorders and immunethyreopathy.
Z Gastroenterol 2001; 39:837-840 - Von Depka Prondzinski M.
Immune Tolerance Therapy in Patients with Acquired Hemophilia
Hematology, 2004; 4:245-257 - Cobas Meyer M, von Depka M.
Labordiagnostik der Sepsis-assoziierten Hämostasestörung.
Intensiv News 2004, im Druck - Cobas-Meyer M, von Depka Prondzinski M.
Neue gerinnungsphysiologische Erkenntnisse in der schweren Sepsis: Sind diese in der Diagnostik nutzbar?
Intensiv Notfallbehandlung 2003; 1:37-43 - Von Depka M.
Erworbene Hämophilie infolge Antikörperbildung gegen FVIII.
Hämostaseologie 2003; 23:28-35 - Von Depka Prondzinski M.
Recombinant Factor VIIa: mode of action and use in Acquired Haemophilia.
Hematology Forum 2002; 4:2-3 - Von Depka Prondzinski M.
NovoSeven: mode of action and use in acquired haemophilia.
Int Care Med 2002; 28:S222-228 - Von Depka Prondzinski M, Karthaus M, Ganser A, Barthels M.
Anticoagulant prophylaxis and therapy in patients with cancer.
Antibiot Chemother. 2000; 50:149-158 - Von Depka Prondzinski M, Ehrenforth S.
New Candidate Gene Polymorphisms in Venous Thrombosis.
J Lab Med 2001; 25:277-283 - Wermes C, von Depka Prondzinski M, Lichtinghagen R, Barthels M, Welte K, Sykora KW.
Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters.
Eur J Pediatr 1999; 158, Suppl 3:143-146 - von Depka Prondzinski M, AuerswaldG, BrackmannHH, Eifrig B, GürtlerL, Heinrichs C, Herrmann FH, Hovy L, Kreuz W, Kurnik K, LenkH, PollmannH, Scharrer I, Syrbe G, Wolf HH, Zimmermann R.
Zertifikationskriterien des/der hämostaseologisch qualifizierten Arztes/Ärztin.
Hämostaseologie 2002; 22:49-50 - H. H. Brackmann, M. von Depka Prondzinski, C. Heinrichs, H. Lenk, I. Scharrer, R. Zimmermann.
Leitlinien zur Qualitätssicherung der Hämophiliebehandlung.
Hämostaseologie 2001, 30:35-36
Druckversion
Online-Services
Wir bieten Ihnen die Möglichkeit, unterschiedliche Auskünfte online einzuholen. So können Sie z.B. ein Rezept anfordern, einen Termin mit uns vereinbaren oder eine Überweisung anfordern.